Skip to main content
SpringerLink
Log in

CTCs for Biomarker and Companion Diagnostic Development

  • Chapter
  • First Online:
Circulating Tumor Cells

Part of the book series: Current Cancer Research ((CUCR))

  • 1580 Accesses

Abstract

Circulating tumor cells (CTCs) were first recognized in the blood of cancer patients by Thomas Ashworth in 1869. Recent advances have propelled CTCs to center stage in diagnostic and translational research, largely owing to advances in isolation technology and increasing sensitivity of the various genomic, transcriptomic, and proteomic platforms. As we enter the era of personalized medicine, it is foreseeable that CTCs will become an integral component of clinical practice to not only understand disease evolution but also match patients with appropriate therapeutics.

The current field is inundated with an enormous amount of data studying diverse aspects of CTC biology. In this chapter, we focus on recent developments in the incorporation of CTCs in oncology clinical studies that suggest promising utility for CTCs as pharmacodynamic and predictive biomarkers that can fundamentally aid decision making in clinical trials. In light of the complexity inherent in codeveloping in vitro diagnostic assays with therapeutic agents, we highlight key challenges and suggest solutions to enable the ultimate goal of developing CTCs as companion diagnostic assays for targeted oncology therapeutics.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717. doi:10.1016/S0140-6736(05)66544-0

    Article  Google Scholar 

  2. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659–1672. doi:10.1056/NEJMoa052306

    Article  CAS  PubMed  Google Scholar 

  3. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673–1684. doi:10.1056/NEJMoa052122

    Article  CAS  PubMed  Google Scholar 

  4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792. doi:10.1056/NEJM200103153441101

    Article  CAS  PubMed  Google Scholar 

  5. Lesko LJ, Atkinson AJ Jr (2001) Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol 41:347–366. doi:10.1146/annurev.pharmtox.41.1.347

    Article  CAS  PubMed  Google Scholar 

  6. El-Osta H, Hong D, Wheler J, Fu S, Naing A, Falchook G, Hicks M, Wen S, Tsimberidou AM, Kurzrock R (2011) Outcomes of research biopsies in phase I clinical trials: the MD Anderson cancer center experience. Oncologist 16(9):1292–1298. doi:10.1634/theoncologist.2011-0043

    Article  PubMed Central  PubMed  Google Scholar 

  7. Lackner MR, Wilson TR, Settleman J (2012) Mechanisms of acquired resistance to targeted cancer therapies. Future Oncol 8(8):999–1014. doi:10.2217/fon.12.86

    Article  CAS  PubMed  Google Scholar 

  8. De Mattos-Arruda L, Cortes J, Santarpia L, Vivancos A, Tabernero J, Reis-Filho JS, Seoane J (2013) Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat Rev Clin Oncol 10(7):377–389. doi:10.1038/nrclinonc.2013.80

    Article  PubMed  Google Scholar 

  9. Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, Kaper F, Dawson SJ, Piskorz AM, Jimenez-Linan M, Bentley D, Hadfield J, May AP, Caldas C, Brenton JD, Rosenfeld N (2012) Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 4(136):136ra168. doi:10.1126/scitranslmed.3003726

    Article  Google Scholar 

  10. Haber DA, Velculescu VE (2014) Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov 4(6):650–661. doi:10.1158/2159-8290.cd-13-1014

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Lorente D, Mateo J, de Bono JS (2014) Molecular characterization and clinical utility of circulating tumor cells in the treatment of prostate cancer. Am Soc Clin Oncol Educ Book 2014:e197–e203. doi:10.14694/EdBook_AM.2014.34.e197

    Article  Google Scholar 

  12. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, Ryan P, Balis UJ, Tompkins RG, Haber DA, Toner M (2007) Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450(7173):1235–1239. doi:10.1038/nature06385

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Punnoose EA, Atwal SK, Spoerke JM, Savage H, Pandita A, Yeh RF, Pirzkall A, Fine BM, Amler LC, Chen DS, Lackner MR (2010) Molecular biomarker analyses using circulating tumor cells. PLoS One 5(9):e12517. doi:10.1371/journal.pone.0012517

    Article  PubMed Central  PubMed  Google Scholar 

  14. Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA, Rothenberg SM, Shah AM, Smas ME, Korir GK, Floyd FP Jr, Gilman AJ, Lord JB, Winokur D, Springer S, Irimia D, Nagrath S, Sequist LV, Lee RJ, Isselbacher KJ, Maheswaran S, Haber DA, Toner M (2010) Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A 107(43):18392–18397. doi:10.1073/pnas.1012539107

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. (2014) Tracking CTCs may improve cancer treatment. Cancer Discov 4(5): 504. doi: 10.1158/2159-8290.CD-ND2014-006

  16. Karabacak NM, Spuhler PS, Fachin F, Lim EJ, Pai V, Ozkumur E, Martel JM, Kojic N, Smith K, Chen PI, Yang J, Hwang H, Morgan B, Trautwein J, Barber TA, Stott SL, Maheswaran S, Kapur R, Haber DA, Toner M (2014) Microfluidic, marker-free isolation of circulating tumor cells from blood samples. Nat Protoc 9(3):694–710. doi:10.1038/nprot.2014.044

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Williams A, Balic M, Datar R, Cote R (2012) Size-based enrichment technologies for CTC detection and characterization. Recent Results Cancer Res 195:87–95. doi:10.1007/978-3-642-28160-0_8

    Article  PubMed  Google Scholar 

  18. Heitzer E, Auer M, Gasch C, Pichler M, Ulz P, Hoffmann EM, Lax S, Waldispuehl-Geigl J, Mauermann O, Lackner C, Hofler G, Eisner F, Sill H, Samonigg H, Pantel K, Riethdorf S, Bauernhofer T, Geigl JB, Speicher MR (2013) Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res 73(10):2965–2975. doi:10.1158/0008-5472.can-12-4140

    Article  CAS  PubMed  Google Scholar 

  19. Yu M, Bardia A, Aceto N, Bersani F, Madden MW, Donaldson MC, Desai R, Zhu H, Comaills V, Zheng Z, Wittner BS, Stojanov P, Brachtel E, Sgroi D, Kapur R, Shioda T, Ting DT, Ramaswamy S, Getz G, Iafrate AJ, Benes C, Toner M, Maheswaran S, Haber DA (2014) Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 345(6193):216–220. doi:10.1126/science.1253533

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Chiu CG, Nakamura Y, Chong KK, Huang SK, Kawas NP, Triche T, Elashoff D, Kiyohara E, Irie RF, Morton DL, Hoon DS (2014) Genome-wide characterization of circulating tumor cells identifies novel prognostic genomic alterations in systemic melanoma metastasis. Clin Chem 60(6):873–885. doi:10.1373/clinchem.2013.213611

    Article  CAS  PubMed  Google Scholar 

  21. Magbanua MJ, Sosa EV, Scott JH, Simko J, Collins C, Pinkel D, Ryan CJ, Park JW (2012) Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer. BMC Cancer 12:78. doi:10.1186/1471-2407-12-78

    Article  PubMed Central  PubMed  Google Scholar 

  22. Paris PL, Kobayashi Y, Zhao Q, Zeng W, Sridharan S, Fan T, Adler HL, Yera ER, Zarrabi MH, Zucker S, Simko J, Chen WT, Rosenberg J (2009) Functional phenotyping and genotyping of circulating tumor cells from patients with castration resistant prostate cancer. Cancer Lett 277(2):164–173. doi:10.1016/j.canlet.2008.12.007

    Article  CAS  PubMed  Google Scholar 

  23. Lohr JG, Adalsteinsson VA, Cibulskis K, Choudhury AD, Rosenberg M, Cruz-Gordillo P, Francis JM, Zhang CZ, Shalek AK, Satija R, Trombetta JJ, Lu D, Tallapragada N, Tahirova N, Kim S, Blumenstiel B, Sougnez C, Lowe A, Wong B, Auclair D, Van Allen EM, Nakabayashi M, Lis RT, Lee GS, Li T, Chabot MS, Ly A, Taplin ME, Clancy TE, Loda M, Regev A, Meyerson M, Hahn WC, Kantoff PW, Golub TR, Getz G, Boehm JS, Love JC (2014) Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol 32(5):479–484. doi:10.1038/nbt.2892

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Ni X, Zhuo M, Su Z, Duan J, Gao Y, Wang Z, Zong C, Bai H, Chapman AR, Zhao J, Xu L, An T, Ma Q, Wang Y, Wu M, Sun Y, Wang S, Li Z, Yang X, Yong J, Su XD, Lu Y, Bai F, Xie XS, Wang J (2013) Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. Proc Natl Acad Sci U S A 110(52):21083–21088. doi:10.1073/pnas.1320659110

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Sieuwerts AM, Kraan J, Bolt-de Vries J, van der Spoel P, Mostert B, Martens JW, Gratama JW, Sleijfer S, Foekens JA (2009) Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR. Breast Cancer Res Treat 118(3):455–468. doi:10.1007/s10549-008-0290-0

    Article  CAS  PubMed  Google Scholar 

  26. Sieuwerts AM, Mostert B, Bolt-de Vries J, Peeters D, de Jongh FE, Stouthard JM, Dirix LY, van Dam PA, Van Galen A, de Weerd V, Kraan J, van der Spoel P, Ramirez-Moreno R, van Deurzen CH, Smid M, Yu JX, Jiang J, Wang Y, Gratama JW, Sleijfer S, Foekens JA, Martens JW (2011) mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clin Cancer Res 17(11):3600–3618. doi:10.1158/1078-0432.ccr-11-0255

    Article  CAS  PubMed  Google Scholar 

  27. Sullivan JP, Nahed BV, Madden MW, Oliveira SM, Springer S, Bhere D, Chi AS, Wakimoto H, Rothenberg SM, Sequist LV, Kapur R, Shah K, Iafrate AJ, Curry WT, Loeffler JS, Batchelor TT, Louis DN, Toner M, Maheswaran S, Haber DA (2014) Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov 4:1299. doi:10.1158/2159-8290.cd-14-0471

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, Concannon KF, Donaldson MC, Sequist LV, Brachtel E, Sgroi D, Baselga J, Ramaswamy S, Toner M, Haber DA, Maheswaran S (2013) Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339(6119):580–584. doi:10.1126/science.1228522

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Yu M, Ting DT, Stott SL, Wittner BS, Ozsolak F, Paul S, Ciciliano JC, Smas ME, Winokur D, Gilman AJ, Ulman MJ, Xega K, Contino G, Alagesan B, Brannigan BW, Milos PM, Ryan DP, Sequist LV, Bardeesy N, Ramaswamy S, Toner M, Maheswaran S, Haber DA (2012) RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature 487(7408):510–513. doi:10.1038/nature11217

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Ramskold D, Luo S, Wang YC, Li R, Deng Q, Faridani OR, Daniels GA, Khrebtukova I, Loring JF, Laurent LC, Schroth GP, Sandberg R (2012) Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells. Nat Biotechnol 30(8):777–782. doi:10.1038/nbt.2282

    Article  PubMed Central  PubMed  Google Scholar 

  31. Kallergi G, Agelaki S, Kalykaki A, Stournaras C, Mavroudis D, Georgoulias V (2008) Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients. Breast Cancer Res 10(5):R80. doi:10.1186/bcr2149

    Article  PubMed Central  PubMed  Google Scholar 

  32. Kim P, Liu X, Lee T, Liu L, Barham R, Kirkland R, Leesman G, Kuller A, Ybarrondo B, Ng SC, Singh S (2011) Highly sensitive proximity mediated immunoassay reveals HER2 status conversion in the circulating tumor cells of metastatic breast cancer patients. Proteome Sci 9(1):75. doi:10.1186/1477-5956-9-75

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  33. Meng S, Tripathy D, Shete S, Ashfaq R, Saboorian H, Haley B, Frenkel E, Euhus D, Leitch M, Osborne C, Clifford E, Perkins S, Beitsch P, Khan A, Morrison L, Herlyn D, Terstappen LW, Lane N, Wang J, Uhr J (2006) uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci U S A 103(46):17361–17365. doi:10.1073/pnas.0608113103

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  34. Miyamoto DT, Lee RJ, Stott SL, Ting DT, Wittner BS, Ulman M, Smas ME, Lord JB, Brannigan BW, Trautwein J, Bander NH, Wu CL, Sequist LV, Smith MR, Ramaswamy S, Toner M, Maheswaran S, Haber DA (2012) Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov 2(11):995–1003. doi:10.1158/2159-8290.cd-12-0222

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Pestrin M, Bessi S, Puglisi F, Minisini AM, Masci G, Battelli N, Ravaioli A, Gianni L, Di Marsico R, Tondini C, Gori S, Coombes CR, Stebbing J, Biganzoli L, Buyse M, Di Leo A (2012) Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. Breast Cancer Res Treat 134(1):283–289. doi:10.1007/s10549-012-2045-1

    Article  CAS  PubMed  Google Scholar 

  36. Riethdorf S, Muller V, Zhang L, Rau T, Loibl S, Komor M, Roller M, Huober J, Fehm T, Schrader I, Hilfrich J, Holms F, Tesch H, Eidtmann H, Untch M, von Minckwitz G, Pantel K (2010) Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 16(9):2634–2645. doi:10.1158/1078-0432.ccr-09-2042

    Article  CAS  PubMed  Google Scholar 

  37. Stebbing J, Payne R, Reise J, Frampton AE, Avery M, Woodley L, Di Leo A, Pestrin M, Krell J, Coombes RC (2013) The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: a proof-of-concept study. PLoS One 8(5):e62543. doi:10.1371/journal.pone.0062543

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  38. Tinhofer I, Hristozova T, Stromberger C, Keilhoiz U, Budach V (2012) Monitoring of circulating tumor cells and their expression of EGFR/phospho-EGFR during combined radiotherapy regimens in locally advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 83(5):e685–e690. doi:10.1016/j.ijrobp.2012.02.009

    Article  CAS  PubMed  Google Scholar 

  39. Wang L, Wang Y, Liu Y, Cheng M, Wu X, Wei H (2009) Flow cytometric analysis of CK19 expression in the peripheral blood of breast carcinoma patients: relevance for circulating tumor cell detection. J Exp Clin Cancer Res 28:57. doi:10.1186/1756-9966-28-57

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  40. Lee J, Kim S, Kim P, Liu X, Lee T, Kim KM, Do IG, Park JO, Park SH, Jang J, Hoe N, Harvie G, Kuller A, Jain A, Meyer G, Leesman G, Park YS, Choi MG, Sohn TS, Bae JM, Lim HY, Singh S, Kang WK (2013) A novel proteomics-based clinical diagnostics technology identifies heterogeneity in activated signaling pathways in gastric cancers. PLoS One 8(1):e54644. doi:10.1371/journal.pone.0054644

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  41. Pluim D, Devriese LA, Beijnen JH, Schellens JH (2012) Validation of a multiparameter flow cytometry method for the determination of phosphorylated extracellular-signal-regulated kinase and DNA in circulating tumor cells. Cytometry A 81(8):664–671. doi:10.1002/cyto.a.22049

    Article  PubMed  Google Scholar 

  42. Ullal AV, Peterson V, Agasti SS, Tuang S, Juric D, Castro CM, Weissleder R (2014) Cancer cell profiling by barcoding allows multiplexed protein analysis in fine-needle aspirates. Sci Transl Med 6(219):219ra219. doi:10.1126/scitranslmed.3007361

    Article  Google Scholar 

  43. de Bono JS, Attard G, Adjei A, Pollak MN, Fong PC, Haluska P, Roberts L, Melvin C, Repollet M, Chianese D, Connely M, Terstappen LW, Gualberto A (2007) Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res 13(12):3611–3616. doi:10.1158/1078-0432.CCR-07-0268

    Article  PubMed  Google Scholar 

  44. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, Beitsch P, Khan A, Euhus D, Osborne C, Frenkel E, Hoover S, Leitch M, Clifford E, Vitetta E, Morrison L, Herlyn D, Terstappen LW, Fleming T, Fehm T, Tucker T, Lane N, Wang J, Uhr J (2004) HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A 101(25):9393–9398. doi:10.1073/pnas.0402993101

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  45. Rossi E, Basso U, Celadin R, Zilio F, Pucciarelli S, Aieta M, Barile C, Sava T, Bonciarelli G, Tumolo S, Ghiotto C, Magro C, Jirillo A, Indraccolo S, Amadori A, Zamarchi R (2010) M30 neoepitope expression in epithelial cancer: quantification of apoptosis in circulating tumor cells by Cell Search analysis. Clin Cancer Res 16(21):5233–5243. doi:10.1158/1078-0432.CCR-10-1449

    Article  CAS  PubMed  Google Scholar 

  46. Wang LH, Pfister TD, Parchment RE, Kummar S, Rubinstein L, Evrard YA, Gutierrez ME, Murgo AJ, Tomaszewski JE, Doroshow JH, Kinders RJ (2010) Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells. Clin Cancer Res 16(3):1073–1084. doi:10.1158/1078-0432.CCR-09-2799

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  47. Luo X, Mitra D, Sullivan RJ, Wittner BS, Kimura AM, Pan S, Hoang MP, Brannigan BW, Lawrence DP, Flaherty KT, Sequist LV, McMahon M, Bosenberg MW, Stott SL, Ting DT, Ramaswamy S, Toner M, Fisher DE, Maheswaran S, Haber DA (2014) Isolation and molecular characterization of circulating melanoma cells. Cell Rep 7(3):645–653. doi:10.1016/j.celrep.2014.03.039

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  48. Fehm T, Becker S, Duerr-Stoerzer S, Sotlar K, Mueller V, Wallwiener D, Lane N, Solomayer E, Uhr J (2007) Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res 9(5):R74. doi:10.1186/bcr1783

    Article  PubMed Central  PubMed  Google Scholar 

  49. Fehm T, Muller V, Aktas B, Janni W, Schneeweiss A, Stickeler E, Lattrich C, Lohberg CR, Solomayer E, Rack B, Riethdorf S, Klein C, Schindlbeck C, Brocker K, Kasimir-Bauer S, Wallwiener D, Pantel K (2010) HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat 124(2):403–412. doi:10.1007/s10549-010-1163-x

    Article  CAS  PubMed  Google Scholar 

  50. Flores LM, Kindelberger DW, Ligon AH, Capelletti M, Fiorentino M, Loda M, Cibas ES, Janne PA, Krop IE (2010) Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer. Br J Cancer 102(10):1495–1502. doi:10.1038/sj.bjc.6605676

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  51. Ignatiadis M, Kallergi G, Ntoulia M, Perraki M, Apostolaki S, Kafousi M, Chlouverakis G, Stathopoulos E, Lianidou E, Georgoulias V, Mavroudis D (2008) Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin Cancer Res 14(9):2593–2600. doi:10.1158/1078-0432.CCR-07-4758

    Article  CAS  PubMed  Google Scholar 

  52. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih IM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA Jr (2014) Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6(224):224ra24. doi:10.1126/scitranslmed.3007094

    Article  PubMed Central  PubMed  Google Scholar 

  53. Carreira S, Romanel A, Goodall J, Grist E, Ferraldeschi R, Miranda S, Prandi D, Lorente D, Frenel JS, Pezaro C, Omlin A, Rodrigues DN, Flohr P, Tunariu N, SdB J, Demichelis F, Attard G (2014) Tumor clone dynamics in lethal prostate cancer. Sci Transl Med 6(254):254ra125. doi:10.1126/scitranslmed.3009448

    Article  PubMed Central  PubMed  Google Scholar 

  54. Danila DC, Pantel K, Fleisher M, Scher HI (2011) Circulating tumors cells as biomarkers: progress toward biomarker qualification. Cancer J 17(6):438–450. doi:10.1097/PPO.0b013e31823e69ac

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  55. Mao X, Shaw G, James SY, Purkis P, Kudahetti SC, Tsigani T, Kia S, Young BD, Oliver RT, Berney D, Prowse DM, Lu YJ (2008) Detection of TMPRSS2:ERG fusion gene in circulating prostate cancer cells. Asian J Androl 10(3):467–473. doi:10.1111/j.1745-7262.2008.00401.x

    Article  CAS  PubMed  Google Scholar 

  56. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371(11):1028–1038. doi:10.1056/NEJMoa1315815

    Article  PubMed Central  PubMed  Google Scholar 

  57. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN, Terstappen LW (2005) Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 23(7):1420–1430. doi:10.1200/JCO.2005.08.140

    Article  PubMed  Google Scholar 

  58. Miller MC, Doyle GV, Terstappen LW (2010) Significance of circulating tumor cells detected by the cell search system in patients with metastatic breast colorectal and prostate cancer. J Oncol 2010:617421. doi:10.1155/2010/617421

    Article  PubMed Central  PubMed  Google Scholar 

  59. Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B, Janni W, Coith C, Beck K, Janicke F, Jackson S, Gornet T, Cristofanilli M, Pantel K (2007) Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the Cell Search system. Clin Cancer Res 13(3):920–928. doi:10.1158/1078-0432.CCR-06-1695

    Article  CAS  PubMed  Google Scholar 

  60. Ravdin PM, Chamness GC (1995) The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers--a review. Gene 159(1):19–27

    Article  CAS  PubMed  Google Scholar 

  61. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177–182

    Article  CAS  PubMed  Google Scholar 

  62. Sundaresan S, Penuel E, Sliwkowski MX (1999) The biology of human epidermal growth factor receptor 2. Curr Oncol Rep 1(1):16–22

    Article  CAS  PubMed  Google Scholar 

  63. Munzone E, Nole F, Goldhirsch A, Botteri E, Esposito A, Zorzino L, Curigliano G, Minchella I, Adamoli L, Cassatella MC, Casadio C, Sandri MT (2010) Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer. Clin Breast Cancer 10(5):392–397. doi:10.3816/CBC.2010.n.052

    Article  CAS  PubMed  Google Scholar 

  64. Turner N, Pestrin M, Galardi F, De Luca F, Malorni L, Di Leo A (2014) Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer? Cancers (Basel) 6(2):684–707. doi:10.3390/cancers6020684

    Article  Google Scholar 

  65. Mansfield EA (2014) FDA perspective on companion diagnostics: an evolving paradigm. Clin Cancer Res 20(6):1453–1457. doi:10.1158/1078-0432.CCR-13-1954

    Article  CAS  PubMed  Google Scholar 

  66. Marton MJ, Weiner R (2013) Practical guidance for implementing predictive biomarkers into early phase clinical studies. BioMed Res Int 2013:891391. doi:10.1155/2013/891391

    Article  PubMed Central  PubMed  Google Scholar 

  67. Rakha EA, Ellis IO (2014) Breast cancer: updated guideline recommendations for HER2 testing. Nat Rev Clin Oncol 11(1):8–9. doi:10.1038/nrclinonc.2013.230

    Article  PubMed  Google Scholar 

  68. Hayashi N, Nakamura S, Tokuda Y, Shimoda Y, Yagata H, Yoshida A, Ota H, Hortobagyi GN, Cristofanilli M, Ueno NT (2012) Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. Int J Clin Oncol 17(2):96–104. doi:10.1007/s10147-011-0260-0

    Article  PubMed  Google Scholar 

  69. Wulfing P, Borchard J, Buerger H, Heidl S, Zanker KS, Kiesel L, Brandt B (2006) HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res 12(6):1715–1720. doi:10.1158/1078-0432.CCR-05-2087

    Article  PubMed  Google Scholar 

  70. Punnoose EA, Atwal S, Liu W, Raja R, Fine BM, Hughes BG, Hicks RJ, Hampton GM, Amler LC, Pirzkall A, Lackner MR (2012) Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res 18(8):2391–2401. doi:10.1158/1078-0432.CCR-11-3148

    Article  CAS  PubMed  Google Scholar 

  71. Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E, Yu M, Chen PI, Morgan B, Trautwein J, Kimura A, Sengupta S, Stott SL, Karabacak NM, Barber TA, Walsh JR, Smith K, Spuhler PS, Sullivan JP, Lee RJ, Ting DT, Luo X, Shaw AT, Bardia A, Sequist LV, Louis DN, Maheswaran S, Kapur R, Haber DA, Toner M (2013) Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med 5(179):179ra147. doi:10.1126/scitranslmed.3005616

    Article  Google Scholar 

  72. Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A’Hern R, Levink R, Coumans F, Moreira J, Riisnaes R, Oommen NB, Hawche G, Jameson C, Thompson E, Sipkema R, Carden CP, Parker C, Dearnaley D, Kaye SB, Cooper CS, Molina A, Cox ME, Terstappen LW, de Bono JS (2009) Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 69(7):2912–2918. doi:10.1158/0008-5472.can-08-3667

    Article  CAS  PubMed  Google Scholar 

  73. Scagliotti G, Stahel RA, Rosell R, Thatcher N, Soria JC (2012) ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development. Eur J Cancer 48(7):961–973. doi:10.1016/j.ejca.2012.02.001

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Jill Spoerke for critical comments on the manuscript, and Carmen Munoz for administrative assistance.

Author information

Authors and Affiliations

  1. Department of Oncology Biomarker Development, Genentech Inc., 1 DNA Way, South San Francisco, CA, 94080, USA

    Shih-Min A. Huang Ph.D. & Mark R. Lackner Ph.D.

Authors
  1. Shih-Min A. Huang Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark R. Lackner Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark R. Lackner Ph.D. .

Editor information

Editors and Affiliations

  1. Jackson Memorial Hospital, University of Miami, Miami, Florida, USA

    Richard J. Cote

  2. University of Miami, Miami, Florida, USA

    Ram H. Datar

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Science+Business Media New York

About this chapter

Cite this chapter

Huang, SM.A., Lackner, M.R. (2016). CTCs for Biomarker and Companion Diagnostic Development. In: Cote, R., Datar, R. (eds) Circulating Tumor Cells. Current Cancer Research. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-3363-1_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-3363-1_15

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-3361-7

  • Online ISBN: 978-1-4939-3363-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation